Año 2019 / Volumen 111 / Número 10
Revisión
Barrett’s esophagus: “All diseases are divine and all are human”

789-794

DOI: 10.17235/reed.2019.6261/2019

Vicente Munitiz Ruiz, Luisa F. Martienz de Haro, Ángeles Ortiz, David Ruiz de Angulo, Pascual Parrilla,

Resumen
Barrett’s esophagus (BE) is a controversial condition. The significance of this condition lies in its premalignant potential, so it is important that clinically applicable biomarkers be identified for early detection and targeted prevention. Dysplasia is currently used as main biomarker, but others most recently surveyed in cancer also include microRNAs. Classically, BE was considered to be an acquired disease related to pathological gastroesophageal acid and bile reflux. However, some cases are associated with genetic predisposition, representing an inherited, familial form of BE. The actual gene, or genes, involved in this condition have not yet been identified. Main therapeutic options include medical treatment and antireflux surgery. Both types of treatment are equally efficient in controlling symptoms and neither is able to cause the metaplastic segment to disappear, which is why the risk of malignancy remains. However, we may use endoscopic radiofrequency to eradicate BE and replace it by the typical squamous epithelium of the esophagus. The currently accepted indications of radiofrequency in BE include low- and high-grade dysplasia, but not Barrett’s esophagus without dysplasia. In conclusion, BE may have two different presentations: environmental (“human”, reflux) or sporadic BE, which is the most common form, and genetic (“divine”, inherited) or familiar BE, less common but with a greater risk for malignancy. As they might be two different diseases, surveillance programs and treatments should also be different.
Share Button
Nuevo comentario
Comentarios
No hay comentarios para este artículo.
Bibliografía
1. Bennett C, Moayyedi P, Corley DA, DeCaestecker J, Falck-Ytter Y, Falk G, et al. BOB CAT: A Large-Scale Review and Delphi Consensus for Management of Barrett's Esophagus With No Dysplasia, Indefinite for, or Low-Grade Dysplasia. Am J Gastroenterol 2015 May;110(5):662-82.
2. Fitzgerald RC, di Pietro M, Ragunath K, et al. British Society of Gastroenterology guidelines on the diagnosis and management of Barrett’s oesophagus. Gut. 2014; 63:7–42.
3. Peters FP, Curvers WL, Rosmolen WD, de Vries CE, Ten Kate FJ, Krishnadath KK. Surveillance history of endoscopically treated patients with early Barrett's neoplasia: nonadherence to the Seattle biopsy protocol leads to sampling error. Dis Esophagus 2008;21(6):475-9.
4. Desai TK, Krishnan K, Samala N, Singh J, Cluley J, Perla S et al. The incidence of oesophageal adenocarcinoma in non-dysplastic Barrett's oesophagus: a meta-analysis. Gut 2012;61(7):970-6.
6. Singh S, Manickam P, Amin AV, Samala N, Schouten LJ, Iyer PG et al. Incidence of esophageal adenocarcinoma in Barrett's esophagus with low-grade dysplasia: a systematic review and meta-analysis.Gastrointest Endosc 2014;79(6):897-909.
7. Parrilla P, Ortiz A, Martinez de Haro LF, Aguayo JL, Ramirez P. Evaluation of the magnitude of gastro-oesophageal reflux in Barrett's oesophagus. Gut 1990 Sep;31(9):964-7.
8. Pera M, Pera M. Experimental Barrett's esophagus and the origin of intestinal metaplasia. Chest Surg Clin N Am 2002;12(1):25-37.
9. Bechi P, Pucciani F, Baldini F, Cosi F, Falciai R, Mazzanti R et al. Long-term ambulatory enterogastric reflux monitoring. Validation of a new fiberoptic technique. Dig Dis Sci 1993;38(7):1297-306.
10. Martinez de Haro L, Ortiz A, Parrilla P, Munitiz V, Molina J, Bermejo J et al. Intestinal metaplasia in patients with columnar lined esophagus is associated with high levels of duodenogastroesophageal reflux. Ann Surg 2001;233(1):34-8.
11. Parrilla P, Liron R, Martinez de Haro LF, Ortiz A, Molina J, De Andrés B. Gastric surgery does not increase the risk of developing Barrett's esophagus. Am J Gastroenterol 1997;92(6):960-3.
12. Munitiz V, Parrilla P, Ortiz A, Martinez de Haro LF, Yelamos J, Molina J. High risk of malignancy in familial Barrett's esophagus: presentation of one family. J Clin Gastroenterol 2008;42(7):806-9.
13. Drovdlic CM, Goddard KA, Chak A, Brock W, Chessler L, King JF et al. Demographic and phenotypic features of 70 families segregating Barrett's oesophagus and oesophageal adenocarcinoma. J Med Genet 2003;40(9):651-6.
14. Chak A, Lee T, Kinnard MF, Brock W, Faulx A, Willis J et al. Familial aggregation of Barrett's oesophagus, oesophageal adenocarcinoma, and oesophagogastric junctional adenocarcinoma in Caucasian adults.Gut 2002;51(3):323-8.
15. Chak A, Ochs-Balcom H, Falk G, Grady WM, Kinnard M, Willis JE et al. Familiality in Barrett's esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal junction. Cancer Epidemiol Biomarkers Prev 2006; 15(9):1668-73.
16. Fecteau RE, Kong J, Kresak A, Brock W, Song Y, Fujioka H et al. Association between germline mutation in VSIG10L and Familial Barrett neoplasia. JAMA Oncol 2016; 2(10): 1333–9.
17. Feber A, Xi L, Luketich JD, Pennathur A, Landreneau RJ, Wu M et al. MicroRNA expression profiles of esophageal cancer. J Thorac Cardiovasc Surg 2008; 135(2): 255–60.
18. Revilla-Nuin B, Parrilla P, Lozano JJ, de Haro LF, Ortiz A, Martínez C et al. Predictive value of MicroRNAs in the progression of Barrett esophagus to adenocarcinoma in a long-term follow-up study. Ann Surg 2013;257(5):886-93.
19. Peters JH. Barrett's esophagus: now what?. Ann Surg 2003;237(3):299-300.
20. Spechler SJ, Lee E, Ahnen D, Goyal RK, Hirano I, Ramirez F et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 2001;285(18):2331-8.
21. Ortiz A, Martinez de Haro LF, Parrilla P, Morales G, Molina J, Bermejo J et al. Conservative treatment versus antireflux surgery in Barrett's oesophagus: long-term results of a prospective study. Br J Surg 1996;83(2):274-8.
22. Parrilla P, Martínez de Haro LF, Ortiz A, Munitiz V, Molina J et al. Long-term results of a randomized prospective study comparing medical and surgical treatment of Barrett’s Esophagus. Ann Surg 2003; 237(3): 291–8.
23. Maret-Ouda J, Konings P, Lagergren J, Brusselaers N. Antireflux surgery and risk of esophageal adenocarcinoma: a systematic review and meta-analysis. Ann Surg 2016;263(2):251-7.
24. Haidry RJ, Dunn JM, Butt MA, Burnell MG, Gupta A, Green S et al. Radiofrequency ablation and endoscopic mucosal resection for dysplastic Barrett's esophagus and early esophageal adenocarcinoma: outcomes of the UK National Halo RFA Registry. Gastroenterology 2013;145(1):87-95.
25. Blot WJ, Tarone RE. Doll and Peto's quantitative estimates of cancer risks: holding generally true for 35 years. J Natl Cancer Inst. 2015 Mar 3;107(4).
5. Arroyo-Martinez Q, Rodriguez-Tellez M, Garcia-Escudero A, Brugal-Medina J, Gonzalez-Campora R, Caunedo Alvarez A. Epidemiology of Barrett's esophagus and esophageal adenocarcinoma in Spain. A unicentric study. Rev Esp Enferm Dig 2016;108(10):609-17.
Instrucciones para citar
Munitiz Ruiz V, Martienz de Haro L, Ortiz Á, Ruiz de Angulo D, Parrilla P. Barrett’s esophagus: “All diseases are divine and all are human”. 6261/2019


Descargar en un gestor de citas

Descargue la cita de este artículo haciendo clic en uno de los siguientes gestores de citas:

Métrica
Este artículo ha sido visitado 854 veces.
Este artículo ha sido descargado 344 veces.

Estadísticas de Dimensions


Estadísticas de Plum Analytics

Ficha Técnica

Recibido: 04/03/2019

Aceptado: 15/04/2019

Prepublicado: 25/09/2019

Publicado: 03/10/2019

Tiempo de revisión del artículo: 35 días

Tiempo de prepublicación: 205 días

Tiempo de edición del artículo: 213 días


Compartir
Este artículo aun no tiene valoraciones.
Valoración del lector:
Valora este artículo:




Asociación Española de Ecografía Digestiva Sociedad Española de Endoscopia Digestiva Sociedad Española de Patología Digestiva
La REED es el órgano oficial de la Sociedad Española de Patología Digestiva, la SociedadEspañola de Endoscopia Digestiva y la Asociación Española de Ecografía Digestiva
Política de cookies Política de Privacidad Aviso Legal © Copyright 2023 y Creative Commons. Revista Española de Enfermedades Digestivas